BR112021012631A2 - Anticorpos anti-ctla4 e métodos de uso dos mesmos - Google Patents
Anticorpos anti-ctla4 e métodos de uso dos mesmosInfo
- Publication number
- BR112021012631A2 BR112021012631A2 BR112021012631A BR112021012631A BR112021012631A2 BR 112021012631 A2 BR112021012631 A2 BR 112021012631A2 BR 112021012631 A BR112021012631 A BR 112021012631A BR 112021012631 A BR112021012631 A BR 112021012631A BR 112021012631 A2 BR112021012631 A2 BR 112021012631A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antibodies
- ctla4 antibodies
- ctla4
- binding proteins
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
anticorpos anti-ctla4 e métodos de uso dos mesmos. a invenção fornece proteínas de ligação anti-ctla4 (por exemplo, anticorpos, anticorpos biespecíficos e receptores quiméricos) e seu uso no tratamento e prevenção de câncer, bem como composições e kits compreendendo as proteínas de ligação anti-ctla4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785111P | 2018-12-26 | 2018-12-26 | |
PCT/US2019/068548 WO2020139926A2 (en) | 2018-12-26 | 2019-12-26 | Anti-ctla4 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021012631A2 true BR112021012631A2 (pt) | 2021-12-14 |
Family
ID=69326740
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021012536-1A BR112021012536A2 (pt) | 2018-12-26 | 2019-12-26 | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
BR112021012631A BR112021012631A2 (pt) | 2018-12-26 | 2019-12-26 | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021012536-1A BR112021012536A2 (pt) | 2018-12-26 | 2019-12-26 | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
Country Status (14)
Country | Link |
---|---|
US (2) | US20220064301A1 (pt) |
EP (2) | EP3902832A2 (pt) |
JP (2) | JP2022516503A (pt) |
KR (2) | KR20210141447A (pt) |
CN (2) | CN113490687A (pt) |
AU (2) | AU2019416220A1 (pt) |
BR (2) | BR112021012536A2 (pt) |
CA (2) | CA3122773A1 (pt) |
EA (2) | EA202191785A1 (pt) |
IL (2) | IL284382A (pt) |
MX (2) | MX2021007768A (pt) |
PH (2) | PH12021551500A1 (pt) |
SG (2) | SG11202106668WA (pt) |
WO (2) | WO2020139926A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4082572A4 (en) * | 2019-12-25 | 2024-03-06 | Bio Thera Solutions Ltd | ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD AND ITS APPLICATION |
EP4236997A1 (en) * | 2020-10-28 | 2023-09-06 | City of Hope | Bispecific anti-cd38-cd3 binders |
TW202317612A (zh) * | 2021-03-01 | 2023-05-01 | 美商艾希利歐發展股份有限公司 | 用於治療癌症的ctla4及pd1/pdl1抗體之組合 |
WO2022187272A1 (en) * | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
JP2024517381A (ja) * | 2021-04-11 | 2024-04-22 | アダジーン インコーポレイテッド | がんを治療するための併用療法 |
US20240116997A1 (en) | 2022-02-23 | 2024-04-11 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
CN115960234B (zh) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | 抗cd16a的抗体及其应用 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
ES2569919T3 (es) | 1999-04-09 | 2016-05-13 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
EP1242438B1 (en) | 1999-12-29 | 2006-11-08 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
HU227217B1 (en) | 2002-12-16 | 2010-11-29 | Genentech Inc | Immunoglobulin variants and uses thereof |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
RS54450B1 (en) | 2003-11-05 | 2016-06-30 | Roche Glycart Ag | ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION |
EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
EP2990053A1 (en) | 2004-01-20 | 2016-03-02 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
EP2385955B1 (en) * | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
KR102492532B1 (ko) * | 2015-05-29 | 2023-01-30 | 아게누스 인코포레이티드 | 항-ctla-4 항체 및 이의 사용 방법 |
ES2963226T3 (es) * | 2016-12-07 | 2024-03-26 | Agenus Inc | Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos |
WO2018207701A1 (ja) | 2017-05-09 | 2018-11-15 | 日東電工株式会社 | 光学部材用組成物、光学部材及び画像表示装置 |
CN108948194B (zh) * | 2017-05-19 | 2023-02-17 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
EA201992755A1 (ru) * | 2017-05-19 | 2020-04-22 | Уси Байолоджикс (Шанхай) Ко. Лтд. | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) |
WO2018218076A1 (en) * | 2017-05-26 | 2018-11-29 | Janux Therapeutics, Inc. | Modified antibodies |
-
2019
- 2019-12-26 US US17/417,244 patent/US20220064301A1/en active Pending
- 2019-12-26 KR KR1020217023751A patent/KR20210141447A/ko unknown
- 2019-12-26 CA CA3122773A patent/CA3122773A1/en active Pending
- 2019-12-26 EP EP19843033.2A patent/EP3902832A2/en active Pending
- 2019-12-26 CN CN201980091038.5A patent/CN113490687A/zh active Pending
- 2019-12-26 BR BR112021012536-1A patent/BR112021012536A2/pt unknown
- 2019-12-26 MX MX2021007768A patent/MX2021007768A/es unknown
- 2019-12-26 WO PCT/US2019/068548 patent/WO2020139926A2/en unknown
- 2019-12-26 US US17/417,239 patent/US20220073613A1/en active Pending
- 2019-12-26 SG SG11202106668WA patent/SG11202106668WA/en unknown
- 2019-12-26 KR KR1020217023750A patent/KR20210142594A/ko unknown
- 2019-12-26 JP JP2021538112A patent/JP2022516503A/ja active Pending
- 2019-12-26 AU AU2019416220A patent/AU2019416220A1/en active Pending
- 2019-12-26 EP EP19845664.2A patent/EP3902833A2/en active Pending
- 2019-12-26 EA EA202191785A patent/EA202191785A1/ru unknown
- 2019-12-26 JP JP2021538124A patent/JP2022516881A/ja active Pending
- 2019-12-26 BR BR112021012631A patent/BR112021012631A2/pt unknown
- 2019-12-26 CA CA3123050A patent/CA3123050A1/en active Pending
- 2019-12-26 WO PCT/US2019/068538 patent/WO2020139920A2/en active Application Filing
- 2019-12-26 SG SG11202106498XA patent/SG11202106498XA/en unknown
- 2019-12-26 MX MX2021007769A patent/MX2021007769A/es unknown
- 2019-12-26 AU AU2019416216A patent/AU2019416216A1/en active Pending
- 2019-12-26 CN CN201980093081.5A patent/CN113490688A/zh active Pending
- 2019-12-26 EA EA202191784A patent/EA202191784A1/ru unknown
-
2021
- 2021-06-23 PH PH12021551500A patent/PH12021551500A1/en unknown
- 2021-06-23 PH PH12021551498A patent/PH12021551498A1/en unknown
- 2021-06-24 IL IL284382A patent/IL284382A/en unknown
- 2021-06-24 IL IL284381A patent/IL284381A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220064301A1 (en) | 2022-03-03 |
IL284381A (en) | 2021-08-31 |
CN113490688A (zh) | 2021-10-08 |
EP3902833A2 (en) | 2021-11-03 |
PH12021551500A1 (en) | 2022-02-28 |
MX2021007768A (es) | 2021-08-24 |
EA202191784A1 (ru) | 2021-10-20 |
WO2020139926A2 (en) | 2020-07-02 |
WO2020139920A2 (en) | 2020-07-02 |
JP2022516503A (ja) | 2022-02-28 |
EP3902832A2 (en) | 2021-11-03 |
BR112021012536A2 (pt) | 2021-09-14 |
PH12021551498A1 (en) | 2022-02-28 |
AU2019416220A1 (en) | 2021-07-22 |
WO2020139920A3 (en) | 2020-08-06 |
KR20210142594A (ko) | 2021-11-25 |
AU2019416216A1 (en) | 2021-07-08 |
MX2021007769A (es) | 2021-09-23 |
KR20210141447A (ko) | 2021-11-23 |
JP2022516881A (ja) | 2022-03-03 |
CN113490687A (zh) | 2021-10-08 |
IL284382A (en) | 2021-08-31 |
SG11202106498XA (en) | 2021-07-29 |
WO2020139926A3 (en) | 2020-08-06 |
SG11202106668WA (en) | 2021-07-29 |
CA3122773A1 (en) | 2020-07-02 |
CA3123050A1 (en) | 2020-07-02 |
EA202191785A1 (ru) | 2021-11-29 |
US20220073613A1 (en) | 2022-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021012631A2 (pt) | Anticorpos anti-ctla4 e métodos de uso dos mesmos | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
AR116718A1 (es) | Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
CO2020010277A2 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
BR112019013468A8 (pt) | Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos | |
UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2018015265A (es) | Metodos para el uso de moleculas de union a cd32b x cd79b en el tratamiento de enfermedades y trastornos inflamatorios. | |
AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos |